A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

This study has been terminated.

(Unable to enroll due to criteria for stable baseline pain)

Sponsor:

Collaborator:

Teva Pharmaceuticals USA

Information provided by (Responsible Party):

OncoGenex Technologies

ClinicalTrials.gov Identifier:

NCT01083615

First received: February 26, 2010

Last updated: February 11, 2014

Last verified: February 2014

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	March 2013
Primary Completion Date:	March 2013 (Final data collection date for primary outcome measure)